Appointment of Dr. Jeffrey Jonas to Compass Pathways Board of Directors

On October 26, 2025, Compass Pathways plc announced the appointment of Dr. Jeffrey Jonas to its Board of Directors, effective October 29, 2025. Dr. Jonas, a partner at Cure Ventures, brings extensive experience in neuroscience and pharmaceutical research. He will serve as a Class II director and join the audit and risk and scientific committees. Dr. Jonas will receive cash and equity compensation, including an option to purchase 52,000 ordinary shares, vesting over three years. Concurrently, Thomas Lönngren will retire from the Board at the end of December 2025. Dr. Jonas's appointment is expected to bolster Compass Pathways' leadership as it advances its COMP360 psilocybin treatment for mental health conditions.